Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Form 8.3 - [KEYWORDS STUDIOS PLC - 09 08 2024] - (CGWL)
-
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
-
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
-
Gold Fields to Acquire Osisko Mining for C$2.16 Billion
-
Gilat Announces the Addition of SCPC Offering to the SkyEdge IV Aquarius Pro Modem
-
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
-
Fortrea Reports Second Quarter 2024 Results
-
ROME Therapeutics to Participate in 2024 Wedbush PacGrow Healthcare Conference
-
West Red Lake Gold Intersects 107.61 g/t Au over 2.5m at Austin and 106.99 g/t Au over 2.35m at McVeigh – Madsen Mine
-
Abacus Life Reports Second Quarter 2024 Results
-
FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults
-
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
-
Beasley Broadcast Group Reports Second Quarter Revenue of $60.4 Million
-
Crew Energy Inc. Announces Strategic Transaction With Tourmaline Oil Corp.
-
Beneficient Announces Enhanced AltAccess Platform With New Machine-Automated Pricing System
-
Lantronix Enters Into Cooperation Agreement With 180 Degree Capital Corp.
-
Marathon Digital Holdings, Inc. Announces Proposed Private Offering of $250 Million of Convertible Senior Notes
-
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
-
Nova Vision Acquisition Corp. Announces Additional Contribution to Trust Account to Extend Period to Consummate Business Combination to September 10, 2024
-
Stop Experimenting with AV1, Start Working with it on Beamr Cloud
-
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
-
Bitdeer Reported Unaudited Financial Results for the Second Quarter of 2024
-
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
Howard Hughes Holdings Inc. Appoints Charley Freericks as President of Phoenix Region
-
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
COMPASS SELF STORAGE OPENS NEW STORAGE CENTER WITH STATE-OF-THE-ART TECHOLOGY IN PLANT CITY, FL
-
Alliance Trust PLC - Net Asset Value
-
Endeavour Silver Reports Guanacevi Primary Ball Mill Trunnion Failure
-
Stephen P. Hearn named to Brown & Brown, Inc. board of directors
-
Stephen P. Hearn named to Brown & Brown, Inc. board of directors
-
Net Asset Value(s)
-
Atavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business Officer
-
Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
-
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
-
Carbon Revolution Supplies Carbon Fiber Wheels For Range Rover Sport SV Edition Two
-
Planet 13 Announces Opening of 27th Florida Dispensary, Located in Ocala
-
Kvika banki hf.: Transaction in relation to a share buyback programme
-
Velcan Holdings: Share buyback program - weekly statement
-
Man Group PLC : Form 8.3 - Keywords Studios plc
-
Man Group PLC : Form 8.3 - Crest Nicholson Holdings plc
-
Man Group PLC : Form 8.3 - Bellway plc
-
KE Holdings Inc. Announces Upsizing and Extension of Share Repurchase Program
-
Gran Tierra Energy Inc. Announces Fifth Consecutive Ecuador Oil Discovery from the Charapa-B6 Well
-
Man Group PLC : Form 8.3 - Redrow plc
-
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
-
Jitterbit’s Harmony EDI Solution Wins Gold for New Product of the Year at the 2024 Stevie Awards for Technology Excellence
-
Man Group PLC : Form 8.3 - Barratt Developments plc
-
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
-
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector
